BioSpace News Archive

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.

Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals today announced four posters and one abstract featuring data for XIFAXAN (rifaximin), TRULANCE (plecanatide) and RELISTOR (methylnaltrexone bromide) that are being presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.

9 Meters Biopharma, Inc. delivered two poster presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, taking place in Charlotte, North Carolina, on October 21-26, 2022.

Butterfly Network, Inc. announced that it will report third quarter 2022 financial results and provide a business update on November 3, 2022, before the market opens.

Motus GI Holdings, Inc. announced today that three abstracts featuring clinical data on the Pure-Vu EVS were presented in poster sessions at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, which is being held October 21 to 26, 2022 in Charlotte, North Carolina.

Veracyte, Inc. (Nasdaq: VCYT) today announced data that provide new insights into thyroid tumor behavior.

Thermo Fisher Scientific, the world leader in serving science, will demonstrate the benefits of collaborating to advance the science of transplantation and connecting breakthroughs to patients this week at the 48th Annual Meeting of the American Society for Histocompatibility & Immunogenetics Conference in Las Vegas.

nRichDX ® has launched two new products designed to help researchers advance liquid biopsy assay development. Both products are designed for use with nRichDX’s Revolution Sample Prep System™.

Transcenta Holding Limited announces that the management team will participate in four upcoming investor conferences in October and November.

ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, recently announced the appointment of Dr. Sridhar Narayan as Vice President responsible for the global Medicinal Chemistry team.